Clinical trials: Pituitary Macroadenoma
Resectable, Non-functioning Pituitary Adenoma
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
The purpose of this study is to evaluate whether therapy with farletuzumab is effective and safe in the treatment of resectable, non-functioning pituitary adenomas.
- Trial name
- NCT01203618
- Testing
- Farletuzumab
- Where
- United States
- Sponsor
- Morphotek
Pituitary Adenoma
OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study.
The aim of the study is to assess accurancy of OCT angiography as a pronostic marker for patients undergoing neurosurgery for compressiver macroadenoma as compared with visual acuity, visual field and OCT.
- Trial name
- FIRST (NCT04074642)
- Testing
- Neurosurgery
- Where
- 2 sites in France
- Volunteers
- 21 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Pituitary Tumor, Optic Chiasm Disorder
Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma
Endoscopic endonasal transsphenoidal surgery is a procedure for the treatment of pituitary macroadenomas that cause visual impairment through optic chiasm compression.
- Trial name
- RetroADEN (NCT03363126)
- Testing
- Endonasal transsphenoidal pituitary tumor removal
- Volunteers
- 88 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Acromegaly
Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control.
- Trial name
- STOP-SST (NCT05149495)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Acromegaly, Pituitary Neoplasm
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
The purpose of this study is to compare the efficacy of Sandostatin LAR® (Registered Trademark) Depot to transsphenoidal surgery in previously untreated acromegalic patients with macroadenomas.
- Trial name
- NCT00001860
- Testing
- Sandostatin LAR Depot versus transsphenoidal surgery
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Craniopharyngiomas, Pituitary Macroadenoma
Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors
Craniopharyngiomas and giant invasive pituitary adenomas, with lesions originating from the pituitary stalk, are frequently associated with intraoperative and postoperative diabetes insipidus (DI).
- Conditions
- Craniopharyngiomas, Pituitary Macroadenoma, Sellar and Suprasellar Masses
- Trial name
- RCT-PIDST (NCT07712328)
- Testing
- Desmopressin (DDAVP), Control
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Zhaoyun Zhang
Pituitary Macroadenoma
Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas
This study is a single arm Phase II pilot trial. Patients enrolled on the trial will undergo implantation of high activity iodine-125 seeds into their pituitary adenoma.
- Trial name
- NCT01444209
- Testing
- Iodine Implants
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Texas Southwestern Medical Center
Acromegaly
One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
This non-interventional retrospective study aims to describe the therapeutic procedures and modalities received by patients and the correlation to hormone status, during a one year follow up from completion of the 2-79-52030-207…
- Trial name
- NCT01471405
- Where
- 18 sites in Czechia, France and 4 more
- Volunteers
- 54 people
- Sponsor
- Ipsen
Acromegaly
Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
The purpose of this study is to evaluate the efficacy of octreotide acetate to decrease GH and IGF-I levels in acromegalic patients, with microadenomas (≤ 10 mm) or macroadenomas (> 10 mm).
- Trial name
- NCT00242541
- Testing
- Octreotide acetate
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Acromegaly is a chronic disease caused by excessive secretion of growth hormone (GH) and mainly due to benign tumour localized in the pituitary gland.
- Trial name
- PRIMARYS (NCT00690898)
- Testing
- Lanreotide autogel 120 mg
- Where
- 27 sites in Belgium, Czechia and 7 more
- Volunteers
- 108 people
- Sponsor
- Ipsen
Pituitary Macroadenoma
Utilization of iMRI for Transsphenoidal Resection of Pituitary Macroadenomas
The investigators are studying the utility of intra-operative magnetic resonance imaging (iMRI) during transsphenoidal pituitary surgery for large macroadenomas by randomizing patients to either an intra-operative MRI after…
- Trial name
- NCT02396810
- Testing
- intra-operative MRI, Transsphenoidal resection of pituitary macroadenoma
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Prolactinoma, Prolactin-Producing Pituitary Tumor
Validation of a Quality of Life Metric "Prolac-10"
This is a short-term validation study of a quality of life metric "Prolac-10" for patients diagnosed with a prolactinoma, undergoing new medical therapy.
- Conditions
- Prolactinoma, Prolactin-Producing Pituitary Tumor, Pituitary Tumor, Prolactinoma Macroadenoma
- Trial name
- Prolac-10 (NCT04106531)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ohio State University
Pituitary Tumor, Pituitary Adenoma
Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
There is a need for improved visualization of presence and extent of pituitary neuroendocrine tumor (PitNET) tissue during transsphenoidal surgery (TSS), especially in tumors invading the cavernous sinus (CS).
- Conditions
- Pituitary Tumor, Pituitary Adenoma, Pituitary Macroadenoma
- Trial name
- DEPARTURE (NCT04212793)
- Testing
- Bevacizumab-IRDye800CW, Molecular Fluorescence Endoscopy platform
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen